kaiser glp-1 coverage 2026 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs 📌 Starting January 1, 2025,

I.ReinerD

A sizeable proportion of the eligible patients in the database could not be PS matched owing to missing HbA1c and weight data and were therefore not included in the analysis

The clinical reality: your provider will choose a Zepbound starting dose based on tolerability and titration goals, not mathematical conversion from your Wegovy dose

For international travel, patients should carry a letter from their healthcare provider explaining the medical necessity of the medication

Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options

Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED